Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2012

View Archived Issues

Johnson & Johnson presents highlights of third quarter 2012

Recent clinical data support approval of canagliflozin

Gene polymorphism linked to acute lung injury in Gram-negative sepsis

Tocilizumab shows positive effects in patients with neuromyelitis optica

Novel PI3K and mTOR inhibitors patented by Pathway Therapeutics

Abbott updates pipeline progress of third quarter 2012

New gamma-secretase modulators prepared at Pfizer

Chugai presents interim phase II results for CH-5424802

Prozymex presents new DPP-I inhibitors

CHMP recommends approval of Krystexxa

New agents for bacterial infections synthesized by Actelion Pharmaceuticals

Natco Pharma prepares new salts of anticancer agent

Actelion submits macitentan NDA

Amgen patents novel pim inhibitors

A novel marker can predict the outcome in osteosarcoma

Alnylam and Genzyme form RNAi therapeutics alliance in Asia

NXT-182 prevents neuronal apoptosis in vitro and increases neurogenesis in vivo

Health Canada approves new drug submission for Cinryze

Derma Sciences to begin phase III DSC-127 program

Astellas Pharma launches Myrbetriq in U.S.

Kaken submits application in Japan for topical antifungal agent

Eisai obtains FDA approval for Fycompa

Ono and Domain Therapeutics enter GPCR collaboration

Health Canada approves Seebri Breezhaler for COPD

Ligand to receive milestone payment from Merck & Co.

Phase I trial of Kevetrin now active

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...